Adult Dosing

• 300 mg IV, over a 30-minute period, every 4 weeks.

• Moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy (adult patients)

• A history of anaphylaxis with anifrolumab-fnia.
• Concomitant use with other biologic therapies, including B-cell-targeted therapies.
• Chronic infection, a history of recurrent infections, or known risk factors for infection.

• Serious and sometimes fatal infections
• Serious hypersensitivity reactions (including anaphylaxis)
• Risk factors for the development or reoccurrence of malignancy
• Avoid concurrent use of live or live-attenuated vaccines

• Serious Infections
• Hypersensitivity Reactions Including Anaphylaxis and Angioedema
• Malignancy
• Herpes Zoster
• Infusion-related Reactions

• Metabolism/Excretion: Unknown.
• Mechanism of Action: binds to subunit 1 of the type I interferon receptor (IFNAR) with high specificity and affinity. Binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs
• Half-life: Unknown.

US Trade Name(s)

• Saphnelo

US Availability

Saphnelo

• Solution for INJ: 150 mg/mL

[Outline]

Allergy & Immunology

Antibodies; Monoclonal